As we step into 2025, we take a moment to reflect on the past few months, which has been a busy and exciting period for Qureight. With new team members, Christmas parties, securing funding, industry recognition, and new partnerships, we’re making progress in our mission to transform clinical trials through deep-learning imaging.
Team
Strengthening our team has been a key focus. Fabio Ferreira and Nicola Dinsdale have joined as Senior Machine Learning Engineers, bringing extensive expertise in AI-driven imaging. Their contributions will enhance our capabilities in refining imaging analysis for clinical trials, supporting our growing portfolio of collaborations. Alongside them, we welcome Debbie Henthorn as our Head of Scientific Operations, responsible for ensuring the scientific side of the company runs efficiently. We have also welcomed Sammy Adenike Shittu, Clinical Project Manager, who will be coordinating trials and working closely with our partners.
With growth comes responsibility. Achieving ISO 27001 certification is a significant milestone, reinforcing our commitment to data security in clinical trials. This internationally recognised accreditation demonstrates our ability to handle sensitive clinical data securely and ensures compliance with global regulatory standards. As we continue to integrate AI into clinical workflows, maintaining the highest level of data protection remains a priority.
To mark the end of a successful year, we gathered as a team for our annual Christmas party – an opportunity to reflect on 2024’s achievements, including securing new funding, expanding partnerships, and strengthening our capabilities. This was a great chance to celebrate our shared successes and strengthen the bonds that make Qureight a collaborative and dynamic workplace.
Events
Beyond internal developments, our work continues to receive industry recognition. In December, our CEO, Dr. Muhunthan Thillai, represented Qureight as a finalist in the techbio category at Health Tech Forward in Barcelona. Shortly after, he spoke at the Investing in Cambridge event at the Wellcome Trust, highlighting how AI-driven imaging is reshaping clinical trials and accelerating drug development.
Qureight’s presence at key industry events extended beyond our leadership team. At the British Thoracic Society (BTS) Winter Meeting, Dr. Hakim Ghani, a physician at Papworth Hospital, presented on our vascular technology and its potential to improve treatment for pulmonary hypertension (PAH). Meanwhile, Muhunthan joined a panel discussion at the Guinness Ventures Breakfast, where he shared insights on the evolving landscape of techbio investment and the impact of AI on clinical research. These opportunities allow us to showcase our work and engage with leading experts driving change in the sector.
Company News
Our recent strategic partnership with Avalyn Pharma has also gained industry attention. This collaboration integrates Qureight’s deep-learning imaging technology into the MIST study for progressive pulmonary fibrosis (PPF), marking the first time AI-driven imaging has been used as an endpoint measure in a PPF clinical trial. This partnership aims to enhance the assessment of disease progression and treatment response, improving the way clinical trials are conducted in fibrotic lung diseases.
Building on this momentum, our collaboration with Vicore Pharma will see our Core Imaging Platform deployed in the Phase 2b ASPIRE study of buloxibutid for Idiopathic Pulmonary Fibrosis (IPF). This partnership builds on our successful work in the Phase 2a Air study, where our imaging technology played a key role in analysing treatment response. The ASPIRE trial will continue this approach, using multiple imaging models to quantify changes in lung fibrosis and assess the efficacy of buloxibutid as a novel therapy for patients with Idiopathic Pulmonary Fibrosis.
Throughout 2024, we built momentum that positions us well for the future, growing our research capabilities, building valuable partnerships, and deepening our collaborations with key institutions. All of this groundwork puts us in a strong position to advance our work in 2025.